Other languages Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Market Closed - Nasdaq Other stock markets 02:00:00 02/05/2024 am IST			5-day change	1st Jan Change
5.33 ^USD	-0.37%		+9.22%	-14.72%

01/04	Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	MT
01/04	HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer	09/01
Affimed N.V. Announces CEO Changes	08/01
Affimed N.V. Announces Management Changes	08/01
Sector Update: Health Care Stocks Mixed Late Afternoon	04/01
Sector Update: Health Care Stocks Gain in Afternoon Trading	04/01
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall	03/01
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.	03/01
Affimed N.V. Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-Treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	11/12
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors	11/12
Affimed Says CFO Resigns, Names Interim Successor	01/12
Affimed N.V. Announces Changes to its Board	30/11
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells	03/11
Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting	02/11
Looming Inflation Report Drags Exchange-Traded Funds, Equity Futures Lower Premarket Tuesday	12/23/12
Affimed Says FDA Granted Fast Track Designation to Combination Therapy to Treat Hodgkin Lymphoma	12/23/12
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma	12/23/12
Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability	22/23/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Other languages

Filters